U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07108868) titled 'A Phase I Dose Finding Study of MB-CART2219.1' on July 24.
Brief Summary: A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
Study Start Date: June 23
Study Type: INTERVENTIONAL
Condition:
Lymphoma
CLL
Acute Lymphoblastic Leukemia, Pediatric
Intervention:
BIOLOGICAL: CAR-T cells targeting CD19 and CD22
Using the 3+3 design, the following dose levels will be assessed:
Dose level 1: 0.5x10e6 CAR-transduced T cells/kg; Dose level 2: 1x10e6 CAR-transduced T cells/kg; Dose level 3: 2x10e6 CAR-transduced T cells/kg; Dose level 0: 0.25x10e6 C...